水通道蛋白4抗体阳性视神经脊髓炎谱系疾病患者中无症状视神经强化的频率:一项大型回顾性队列研究
该回顾性队列研究纳入2000至2019年在Mayo Clinic评估的100例AQP4-IgG阳性NMOSD患者,由盲法阅片者评估198次眼眶MRI。发作间期视神经强化见于16.8%的扫描,多位于既往发作部位,仅1.8%为新发无症状病灶;有无发作间期强化者的视力无显著差异。
要点
- 发作间期视神经强化见于18/107次(16.8%)扫描,中位距发作192.5天。
- 15次扫描强化位于既往发作部位,病灶长度缩短但位置不变。
- 仅2次扫描(1.8%)为新发无症状强化,另有1例强化早于可检测的眼部异常15天。
核心结论
- 无症状视神经强化发生于17%的NMOSD患者,主要位于既往视神经炎发作部位,可能代表间歇性血脑屏障破坏或亚临床视神经炎。
- 新发无症状强化仅见于2%的患者。
- NMOSD治疗临床试验在评估疗效时需要盲法复发裁定,并应认识到视神经炎患者可出现无症状视神经强化。
研究设计与样本
- 回顾性队列研究,2000至2019年在Mayo Clinic进行,中位随访5.5年(范围1-35年)。
- 纳入100例AQP4-IgG阳性视神经炎患者,共识别198次MRI扫描,其中107次发作间期MRI来自78例独立患者。
- 眼眶MRI由神经放射科医生、神经眼科医生和神经免疫科医生在不知临床病史的情况下审阅。
主要发现
- 发作间期视神经强化(发作后>30天)见于18/107次扫描(16.8%),中位距发作192.5天(范围33-2943天)。
- 15次扫描强化位于既往发作部位,病灶位置不变但长度缩短。
- 2次扫描(1.8%)显示新发无症状病灶,此前扫描无强化。
- 第3例患者有主观视物模糊,MRI显示强化早于15天后检查发现的可检测眼部异常。
- 有无发作间期视神经强化者在前次发作最低视力(logMAR视力1.7 vs 2.1,p=0.79)和长期视力(logMAR视力0.4 vs 0.2,p=0.56)上均无差异。
临床怎么用
- NMOSD治疗临床试验在评估疗效时需要盲法复发裁定。
- 应认识到视神经炎患者可出现无症状视神经强化。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Asymptomatic or persistent optic nerve enhancement in aquaporin-4 (AQP4)-immunoglobulin G (IgG)-positive neuromyelitis optica spectrum disorder (NMOSD) is thought to be rare. Improved understanding may have important implications for assessment of treatment efficacy in clinical trials and in clinical practice. Our objective was to characterize NMOSD interattack optic nerve enhancement. METHODS: This was a retrospective cohort study performed between 2000 and 2019 (median follow-up 5.5 [range 1-35] years) of patients with AQP4-IgG-positive optic neuritis (ON) evaluated at Mayo Clinic. MRI orbits were reviewed by a neuroradiologist, neuro-ophthalmologist, and neuroimmunologist blinded to the clinical history. Interattack optic nerve enhancement (>30 days after attack) was measured. The correlation between interattack enhancement and Snellen visual acuity (VA), converted to logarithm of the minimum angle of resolution (logMAR), at attack and at follow-up were assessed. RESULTS: A total of 198 MRI scans in 100 patients with AQP4-IgG+ NMOSD were identified, with 107 interattack MRIs from 78 unique patients reviewed. Seven scans were performed before any ON (median 61 days before attack [range 21-271 days]) and 100 after ON (median 400 days after attack [33-4,623 days]). Optic nerve enhancement was present on 18/107 (16.8%) interattack scans (median 192.5 days from attack [33-2,943]) of patients with preceding ON. On 15 scans, enhancement occurred at the site of prior attacks; the lesion location was unchanged, but the lesion length was shorter. Two scans (1.8%) demonstrated new asymptomatic lesions (prior scan demonstrated no enhancement). In a third patient with subjective blurry vision, MRI showed enhancement preceding detectable eye abnormalities on examination noted 15 days later. There was no difference in VA at preceding attack nadir (logMAR VA 1.7 vs 2.1; p = 0.79) or long-term VA (logMAR VA 0.4 vs 0.2, p = 0.56) between those with and without interattack optic nerve enhancement. DISCUSSION: Asymptomatic optic nerve enhancement occurred in 17% of patients with NMOSD predominantly at the site of prior ON attacks and may represent intermittent blood-brain barrier breakdown or subclinical ON. New asymptomatic enhancement was seen only in 2% of patients. Therapeutic clinical trials for NMOSD require blinded relapse adjudication when assessing treatment efficacy, and it is important to recognize that asymptomatic optic nerve enhancement can occur in patients with ON.
引用
- Shah SS, Morris P, Buciuc M, et al. Frequency of Asymptomatic Optic Nerve Enhancement in a Large Retrospective Cohort of Patients With Aquaporin-4+ NMOSD. Neurology. 2022. PMID: 35697504. doi:10.1212/WNL.0000000000200838
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。